Eli Lilly reports positive Phase 3b results for EBGLYSS, showing significant skin clearance and symptom relief for patients with hand and foot atopic dermatitis.
Positive Phase 3b data for EBGLYSS in hand and foot atopic dermatitis supports Lilly's dermatology franchise and may drive near-term sentiment.
Eli Lilly's EBGLYSS monotherapy achieved its primary endpoint in a Phase 3b study, with over 50% of patients reaching clear or almost clear skin on hands and feet by Week 16. The treatment also demonstrated rapid efficacy, providing significant itch and pain relief as early as one month into the trial.
The study met its primary endpoint, with more than half of the participants achieving clear or almost clear skin on their hands and feet by the 16-week mark.